U.S. Court Combines Takeda Suits Over Actos Bladder-Cancer Ties
This article was originally published in PharmAsia News
Executive Summary
A U.S. court has combined a pair of suits against Takeda Pharmaceuticals over its Actos (pioglitazone) type 2 diabetes drug into one trial to determine assertions it causes bladder cancer.